Systemic corticosteroids for management of ‘long-COVID’: an evaluation after 3 months of treatment

<a href=''>Casa vettore creata da pikisuperstar -</a>
Submitted: June 16, 2021
Accepted: September 28, 2021
Published: November 3, 2021
Abstract Views: 7868
PDF: 2433
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Some patients even 4 weeks after Corona Virus Disease 2019 (COVID-19) remain to be symptomatic and are known as “long-COVID”. In the present study we performed the follow up evaluation at 3 months of long-COVID patients, after treatment with systemic steroids. During the study duration, out of the 4,542 patients managed in the outpatient department of the particular unit, there were 49 patients of Long-COVID. The patients having abnormal computed tomography (CT) alongwith resting hypoxia or exertional desaturation were treated with systemic steroid (deflazacort) in tapering doses for 8-10 weeks. We retrospectively analysed the clinical and radiological findings of these patients at first presentation and at about 3 months of follow up visit. On follow up, all the 49 long-COVID patients showed improvement. The occurrence of breathlessness decreased from 91.83% to 44.89% (p<0.001) and cough from 77.55% to 8.16% (p<0.001). Twenty-four patients were prescribed systemic steroids. Out of these, nearly 58% patients had MMRC grade 4 breathlessness, which decreased to < 2 MMRC in about 86% of these patients. MMRC grade (median) decreased from 3 to 1 (p<0.001). Majority of patients who were tachypnoeic and hypoxic at rest (n=7) showed improvement (71%), post-treatment with corticosteroids. Occurrence of normal chest X-ray increased from 12% to 71% (p<0.001). All these patients had abnormal CT thorax initially, and post-treatment 25% had normal CT thorax. Hence, we conclude that systemic steroids are helpful in hastening recovery of select subset of long-COVID patients. Simultaneously, we should be cautious of immunosuppressive effects of steroids like tuberculosis reactivation, especially in tuberculosis endemic countries. These findings have therapeutic implications and may serve as guidance for future approach to the management of ‘long-COVID’ with pulmonary sequalae.



PlumX Metrics


Download data is not yet available.


World Health Organization. Coronavirus Disease (COVID-19) Dashboard. Last accessed: 14th May 2021. Available from:
Huang G, Gong T, Wang G, et al. Timely diagnosis and treatment shortens the time to resolution of coronavirus disease (covid-19) pneumonia and lowers the highest and last CT scores from sequential chest CT. AJR Am J Roentgenol 2020;215:367-73. DOI:
Gandhi RT, Lynch JB, del Rio C. Mild or moderate Covid-19. N Engl J Med 2020;383:1757–66. DOI:
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506. DOI:
BMJ Best Practice. Coronavirus disease 2019 (COVID-19) - symptoms, diagnosis and treatment. Last accessed: 13th May 2021. Available from:
Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397:220–32. DOI:
Abdallah SJ, Voduc N, Corrales-Medina VF, et al. Symptoms, pulmonary function and functional capacity four months after covid-19. Ann Am Thor Soc 2021;18:1912-7. DOI:
Infectious Diseases Society of America. Post COVID conditions (e.g. long COVID). 2021. Last accessed: 8th May 2021. Available from:
National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline [NG188]. 2020. Last accessed: 4th May 2021. Available from:
Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect 2020;81:e4–6. DOI:
Carfì A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 2020;324:603–5. DOI:
Wu X, Liu X, Zhou Y, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med 2021;9:747-54. DOI:
Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63:v1-58. DOI:
Antonisamy A, Premkumar P, Christopher S. Principles and practice of biostatistics. Elsevier India; 2017.
Zhang P, Li J, Liu H, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res 2020;8:8. DOI:
Kumar R, Behera D, Jindal SK, et al. Post-COVID-19 respiratory management: Expert panel report. Respiratory management. Indian J Chest Dis Allied Sci 2020;62:179-91.
Goel N, Goyal N, Kumar R. Clinico-radiological evaluation of post COVID-19 at a tertiary pulmonary care centre in Delhi, India. Monaldi Arch Chest Dis 2021;91:1682. DOI:
Guan W, Liang W, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547. DOI:
Goel N, Spalgais S, Mrigpuri P, et al. Characteristics of COVID-19 at a non-COVID tertiary pulmonary care centre in Delhi, India. Monaldi Arch Chest Dis 2020;90:1568. DOI:
Mrigpuri P, Sonal S, Spalgais S, et al. Uncontrolled diabetes mellitus: A risk factor for post COVID fibrosis. Monaldi Arch Chest Dis 2021;91:1607. DOI:
Apicella M, Campopiano MC, Mantuano M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol 2020;8:782-92. DOI:
Hayden MR. An immediate and long-term complication of COVID-19 may be type 2 diabetes mellitus: The central role of β-Cell dysfunction, apoptosis and exploration of possible mechanisms. Cells 2020;9:2475. DOI:
Myall KJ, Mukherjee B, Castanheira AM, et al. Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Ann Am Thorac Soc 2021;18:799–806. DOI:
Goel N, Goyal N, Kumar R. Insights in the management of long COVID-19: preliminary observations. Indian J Chest Dis Allied Sci 2021;63:65-73.
Han X, Fan Y, Alwalid O, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology 2021;299:E177–86. DOI:

Supporting Agencies


How to Cite

Goel, Nitin, Nitesh Goyal, Ravishankar Nagaraja, and Raj Kumar. 2021. “Systemic Corticosteroids for Management of ‘long-COVID’: An Evaluation After 3 Months of Treatment”. Monaldi Archives for Chest Disease 92 (2).